Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

1.2K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.2K
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

644
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
644
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

876
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
876
Cholinergic Antagonists: Therapeutic Uses01:26

Cholinergic Antagonists: Therapeutic Uses

713
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:    
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
713
Chemical Synapses01:26

Chemical Synapses

8.7K
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
8.7K
Direct-Acting Cholinergic Agonists: Therapeutic Uses01:11

Direct-Acting Cholinergic Agonists: Therapeutic Uses

689
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
689

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comprehensive Care Goals in Myasthenia Gravis: Expert Consensus Recommendations Using the RAND/UCLA Appropriateness Method.

Neurology. Clinical practice·2026
Same author

Incremental health care resource utilization, costs, and predictors of high costs in generalized myasthenia gravis.

Journal of managed care & specialty pharmacy·2026
Same author

Economic Evaluation of Thymectomy for the Treatment of Nonthymomatous Myasthenia Gravis.

JAMA network open·2026
Same author

Burden of glucocorticoid use in commercially insured adults with generalized myasthenia gravis in the United States: A retrospective claims-based analysis.

Medicine·2026
Same author

ENGAGE: Analyzing the value of virtual reality in a patient-centric immersive learning program in myasthenia gravis for healthcare professionals.

Frontiers in neurology·2026
Same author

Urinary dysfunction in myasthenia Gravis: a cross-sectional case-control study.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·2026

Related Experiment Video

Updated: Jun 5, 2025

Engineering and Characterization of an Optogenetic Model of the Human Neuromuscular Junction
11:07

Engineering and Characterization of an Optogenetic Model of the Human Neuromuscular Junction

Published on: April 14, 2022

2.3K

Myasthenia gravis: The evolving therapeutic landscape.

Gil I Wolfe1, Jonathan E Hanson1, Nicholas J Silvestri1

  • 1From the Dept. of Neurology, Jacobs School of Medicine and Biomedical Sciences, Univ. at Buffalo, State University of New York, Buffalo, NY, USA.

Eneurologicalsci
|December 9, 2024
PubMed
Summary

Recent advancements offer new pharmacological treatments for generalized myasthenia gravis (gMG). Novel therapies like complement inhibitors and neonatal Fc receptor antagonists show long-term effectiveness and reduce steroid dependency in gMG management.

Keywords:
ComplementMyasthenia gravisNeonatal Fc receptorTherapeutics

More Related Videos

Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

12.3K
The Neuromuscular Junction: Measuring Synapse Size, Fragmentation and Changes in Synaptic Protein Density Using Confocal Fluorescence Microscopy
12:18

The Neuromuscular Junction: Measuring Synapse Size, Fragmentation and Changes in Synaptic Protein Density Using Confocal Fluorescence Microscopy

Published on: December 26, 2014

21.6K

Related Experiment Videos

Last Updated: Jun 5, 2025

Engineering and Characterization of an Optogenetic Model of the Human Neuromuscular Junction
11:07

Engineering and Characterization of an Optogenetic Model of the Human Neuromuscular Junction

Published on: April 14, 2022

2.3K
Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

12.3K
The Neuromuscular Junction: Measuring Synapse Size, Fragmentation and Changes in Synaptic Protein Density Using Confocal Fluorescence Microscopy
12:18

The Neuromuscular Junction: Measuring Synapse Size, Fragmentation and Changes in Synaptic Protein Density Using Confocal Fluorescence Microscopy

Published on: December 26, 2014

21.6K

Area of Science:

  • Neurology
  • Immunology
  • Pharmacology

Background:

  • Generalized myasthenia gravis (gMG) is a chronic autoimmune neuromuscular disease.
  • Treatment options for gMG have historically been limited, often relying on corticosteroids.
  • Recent years have seen significant expansion in therapeutic strategies for gMG.

Purpose of the Study:

  • To summarize recent pharmacological advancements in generalized myasthenia gravis (gMG) management.
  • To outline the current and potential future use of novel gMG therapies.
  • To highlight key findings from Phase 3 studies and open-label extensions.

Main Methods:

  • Review of recent clinical trial data for novel gMG therapies.
  • Analysis of long-term efficacy and safety from open-label extension studies.
  • Synthesis of information on complement inhibitors and neonatal Fc receptor antagonists.

Main Results:

  • Several new pharmacological agents, including complement inhibitors and neonatal Fc receptor antagonists, are now available for gMG.
  • Phase 3 studies and subsequent open-label extensions demonstrate long-term effectiveness of these agents.
  • Observed benefits include a significant reduction in the need for corticosteroid therapy.

Conclusions:

  • The pharmacological landscape for gMG has been transformed by new treatment options.
  • These novel therapies offer sustained efficacy and improved patient outcomes.
  • Future management of gMG will likely involve increased utilization of these advanced pharmacological agents.